Working together to develop a screening platform to enhance the detection and management of Alzheimer’s disease.
PREDICTOM is an international across sector initiative to bring dementia diagnostics closer to the public through a customisable cognitive and biomarker screening platform.
Latest news
News
Home-Based Alzheimer's Blood Testing Shows Promise, but Collecting Quality Samples Remains a Challenge
Could older adults one day participate in Alzheimer's screening without leaving home? Researchers behind the European PREDICTOM project are exploring that possibility through remote blood collection, but new findings suggest that the biggest hurdle may be getting a good blood sample in the first place.
News
🎬 PREDICTOM launches video series exploring the future of early dementia detection
What if Alzheimer's disease could be detected years before symptoms appear? In a newly launched nine-part video series "Predicting Dementia Before It Starts", experts from across PREDICTOM explore how advances in biomarkers, artificial intelligence, brain imaging and digital technologies, and patient involvement could enable earlier and more accurate detection of Alzheimer's disease.
News
🤔 How Participants Move from Level 1 to Level 2 in PREDICTOM?
PREDICTOM applies a risk enrichment strategy to support scalable early detection of Alzheimer’s disease while ensuring that healthcare resources are deployed where they add most value. Movement from Level 1 to Level 2 is based on predictive risk modelling using routine primary care data, enabling population wide reach combined with targeted depth.
PREDICTOM Study Progress
This page provides regularly updated information on the progress of the PREDICTOM study for everyone interested in following its development. The tracker will show progress for both Level 1 and Level 2 as the study advances.
Our mission
PREDICTOM will identify scalable biosignatures for early and accurate diagnosis of Alzheimer’s disease and personalized preventive interventions.